Your browser doesn't support javascript.
loading
Tumour stage distribution and survival of malignant melanoma in Germany 2002-2011.
Schoffer, Olaf; Schülein, Stefanie; Arand, Gerlinde; Arnholdt, Hans; Baaske, Dieter; Bargou, Ralf C; Becker, Nikolaus; Beckmann, Matthias W; Bodack, Yves; Böhme, Beatrix; Bozkurt, Tayfun; Breitsprecher, Regine; Buchali, Andre; Burger, Elke; Burger, Ulrike; Dommisch, Klaus; Elsner, Gudrun; Fernschild, Karin; Flintzer, Ulrike; Funke, Uwe; Gerken, Michael; Göbel, Hubert; Grobe, Norbert; Gumpp, Vera; Heinzerling, Lucie; Kempfer, Lana Raffaela; Kiani, Alexander; Klinkhammer-Schalke, Monika; Klöcking, Sabine; Kreibich, Ute; Knabner, Katrin; Kuhn, Peter; Lutze, Stine; Mäder, Uwe; Maisel, Tanja; Maschke, Jan; Middeke, Martin; Neubauer, Andreas; Niedostatek, Antje; Opazo-Saez, Anabelle; Peters, Christoph; Schell, Beatrice; Schenkirsch, Gerhard; Schmalenberg, Harald; Schmidt, Peter; Schneider, Constanze; Schubotz, Birgit; Seide, Anika; Strecker, Paul; Taubenheim, Sabine.
Afiliação
  • Schoffer O; Cancer Epidemiology, University Cancer Center, Technische Universität Dresden, Dresden, Germany. olaf.schoffer@tum.de.
  • Schülein S; Epidemiology, Department of Sport and Health Sciences, Technical University of Munich, Georg-Brauchle-Ring 56, 80992, Munich, Germany. olaf.schoffer@tum.de.
  • Arand G; Cancer Epidemiology, University Cancer Center, Technische Universität Dresden, Dresden, Germany.
  • Arnholdt H; Epidemiology, Department of Sport and Health Sciences, Technical University of Munich, Georg-Brauchle-Ring 56, 80992, Munich, Germany.
  • Baaske D; Onkologischer Schwerpunkt (OSP) Göppingen, Göppingen, Germany.
  • Bargou RC; Tumour Centre Augsburg, Augsburg, Germany.
  • Becker N; Tumour Centre Chemnitz, Chemnitz, Germany.
  • Beckmann MW; Tumour Centre Würzburg, Würzburg, Germany.
  • Bodack Y; National Centre for Tumour Diseases (NCT) Heidelberg, Heidelberg, Germany.
  • Böhme B; Tumour Centre Erlangen-Nürnberg, Erlangen, Germany.
  • Bozkurt T; Onkologische Qualitätssicherung (QS) in Westfalen-Lippe, Münster, Germany.
  • Breitsprecher R; Regional Clinical Cancer Registry Magdeburg, Magdeburg, Germany.
  • Buchali A; Tumour Centre Koblenz, Koblenz, Germany.
  • Burger E; Tumour Centre Vorpommern, Greifswald, Germany.
  • Burger U; Tumour Centre Brandenburg, Frankfurt (Oder), Germany.
  • Dommisch K; Regional Clinical Cancer Registry Magdeburg, Magdeburg, Germany.
  • Elsner G; Tumour Centre Jena, Jena, Germany.
  • Fernschild K; Tumour Centre Schwerin, Schwerin, Germany.
  • Flintzer U; Onkologischer Schwerpunkt (OSP) Göppingen, Göppingen, Germany.
  • Funke U; Suedharz Klinikum Nordhausen gGmbH, Nordhausen, Germany.
  • Gerken M; Tumour Centre Neubrandenburg, Neubrandenburg, Germany.
  • Göbel H; Tumour Centre Gera, Gera, Germany.
  • Grobe N; Tumour Centre Regensburg, Regensburg, Germany.
  • Gumpp V; Tumour Centre Erfurt, Erfurt, Germany.
  • Heinzerling L; Tumour Centre Neubrandenburg, Neubrandenburg, Germany.
  • Kempfer LR; Tumour Centre Freiburg/Comprehensive Cancer Centre Freiburg (CCCF), Freiburg im Breisgau, Germany.
  • Kiani A; Tumour Centre Erlangen-Nürnberg, Erlangen, Germany.
  • Klinkhammer-Schalke M; National Centre for Tumour Diseases (NCT) Heidelberg, Heidelberg, Germany.
  • Klöcking S; Tumour Centre Oberfranken, Bayreuth, Germany.
  • Kreibich U; Tumour Centre Regensburg, Regensburg, Germany.
  • Knabner K; Tumour Centre Rostock, Rostock, Germany.
  • Kuhn P; Cancer Register of Southwest Saxony, Zwickau, Zwickau, Germany.
  • Lutze S; Suedharz Klinikum Nordhausen gGmbH, Nordhausen, Germany.
  • Mäder U; Tumour Centre Ulm/Comprehensive Cancer Centre Ulm (CCCU), Ulm, Germany.
  • Maisel T; Tumour Centre Vorpommern, Greifswald, Germany.
  • Maschke J; Tumour Centre Würzburg, Würzburg, Germany.
  • Middeke M; Tumour Centre Oberfranken, Bayreuth, Germany.
  • Neubauer A; Tumour Centre Görlitz, Görlitz, Germany.
  • Niedostatek A; Department of Dermatology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
  • Opazo-Saez A; Comprehensive Cancer Centre (CCC) Marburg, Marburg, Germany.
  • Peters C; Comprehensive Cancer Centre (CCC) Marburg, Marburg, Germany.
  • Schell B; Regional Clinical Cancer Registry Dresden, Dresden, Germany.
  • Schenkirsch G; Tumour Centre Schwerin, Schwerin, Germany.
  • Schmalenberg H; Tumour Centre Freiburg/Comprehensive Cancer Centre Freiburg (CCCF), Freiburg im Breisgau, Germany.
  • Schmidt P; Tumour Centre Gera, Gera, Germany.
  • Schneider C; Tumour Centre Augsburg, Augsburg, Germany.
  • Schubotz B; Tumour Centre Jena, Jena, Germany.
  • Seide A; Klinisches Krebsregister Halle, Halle, Germany.
  • Strecker P; Tumour Centre Brandenburg, Frankfurt (Oder), Germany.
  • Taubenheim S; Tumour Centre Chemnitz, Chemnitz, Germany.
BMC Cancer ; 16(1): 936, 2016 12 05.
Article em En | MEDLINE | ID: mdl-27919243
BACKGROUND: Over the past two decades, there has been a rising trend in malignant melanoma incidence worldwide. In 2008, Germany introduced a nationwide skin cancer screening program starting at age 35. The aims of this study were to analyse the distribution of malignant melanoma tumour stages over time, as well as demographic and regional differences in stage distribution and survival of melanoma patients. METHODS: Pooled data from 61 895 malignant melanoma patients diagnosed between 2002 and 2011 and documented in 28 German population-based and hospital-based clinical cancer registries were analysed using descriptive methods, joinpoint regression, logistic regression and relative survival. RESULTS: The number of annually documented cases increased by 53.2% between 2002 (N = 4 779) and 2011 (N = 7 320). There was a statistically significant continuous positive trend in the proportion of stage UICC I cases diagnosed between 2002 and 2011, compared to a negative trend for stage UICC II. No trends were found for stages UICC III and IV respectively. Age (OR 0.97, 95% CI 0.97-0.97), sex (OR 1.18, 95% CI 1.11-1.25), date of diagnosis (OR 1.05, 95% CI 1.04-1.06), 'diagnosis during screening' (OR 3.24, 95% CI 2.50-4.19) and place of residence (OR 1.23, 95% CI 1.16-1.30) had a statistically significant influence on the tumour stage at diagnosis. The overall 5-year relative survival for invasive cases was 83.4% (95% CI 82.8-83.9%). CONCLUSIONS: No distinct changes in the distribution of malignant melanoma tumour stages among those aged 35 and older were seen that could be directly attributed to the introduction of skin cancer screening in 2008.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Melanoma Tipo de estudo: Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Revista: BMC Cancer Assunto da revista: NEOPLASIAS Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Alemanha País de publicação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Melanoma Tipo de estudo: Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Revista: BMC Cancer Assunto da revista: NEOPLASIAS Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Alemanha País de publicação: Reino Unido